- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01685840
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT)
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4Z6
- Foothills Medical Centre
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Vancouver General Hospital
-
Vancouver, British Columbia, Kanada, V6Z 1Y6
- Saint Paul's Hospital
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8L 2X2
- Hamilton Health Sciences
-
Toronto, Ontario, Kanada, M5B 1W8
- St. Michaels Hospital
-
-
-
-
Alabama
-
Huntsville, Alabama, Stany Zjednoczone, 35801
- The Heart Center PC
-
-
California
-
Sacramento, California, Stany Zjednoczone, 95819
- Sutter Memorial Hospital
-
San Diego, California, Stany Zjednoczone, 92037
- University of California San Diego Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Yale University School of Medicine
-
-
Florida
-
Coral Springs, Florida, Stany Zjednoczone, 33065
- Holy Cross Medical Group
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33308
- Holy Cross Hospital
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University
-
Augusta, Georgia, Stany Zjednoczone, 30901
- University Cardiology Associates, LLC
-
-
Illinois
-
Aurora, Illinois, Stany Zjednoczone, 60504
- Fox Valley Clinical Research Center, LLC
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Krannert Institute of Cardiology
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- University of Maryland
-
Beltsville, Maryland, Stany Zjednoczone, 20705
- Metropolitan Cardiovascular Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Beth Israel Medical Center
-
Haverhill, Massachusetts, Stany Zjednoczone, 01830
- Pentucket Medical Associates
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic
-
-
Missouri
-
San Luis, Missouri, Stany Zjednoczone, 63112
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Cherry Hill, New Jersey, Stany Zjednoczone, 08034
- Cardiovascular Associates of the Delaware Valley
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Robert Wood Johnson University Hospital
-
Sewell, New Jersey, Stany Zjednoczone, 08080
- Cardiovascular Associates of the Delaware Valley
-
-
New York
-
Bronx, New York, Stany Zjednoczone, 10461
- Jacobi Medical Center
-
Bronx, New York, Stany Zjednoczone, 10457
- Bronx-Lebanon Hospital Center
-
Bronx, New York, Stany Zjednoczone, 10467
- Albert Einstein University Hospital
-
Brooklyn, New York, Stany Zjednoczone, 11215
- New York Methodist Hospital
-
Saratoga Springs, New York, Stany Zjednoczone, 12866
- Saratoga Cardiology Associates
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, Stany Zjednoczone, 28204
- Novant Health Heart and Vascular Institute
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
Greensboro, North Carolina, Stany Zjednoczone, 27401
- LeBauer Cardiovascular Research Foundation
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45267
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Stany Zjednoczone, 17011
- Capitol Area Research, LLC
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19102
- Drexel University College of Medicine
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Pittsburg, Pennsylvania, Stany Zjednoczone, 15212
- Allegheny-Singer Research Institute
-
-
South Carolina
-
Anderson, South Carolina, Stany Zjednoczone, 29621
- AnMed Health Medical Center
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75390
- University of Texas Southwestern Medical Center Dallas
-
-
Utah
-
Murray, Utah, Stany Zjednoczone, 84157
- Intermountain Medical Center
-
-
Virginia
-
Chesapeake, Virginia, Stany Zjednoczone, 23320
- Cardiovascular Associates, Ltd.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 18 years or older
- Most recent LVEF to be ≤ 40% by any method within 12 months of randomization.
- High risk heart failure as defined by the following criteria:
A Heart Failure Event in the prior 12 months, defined as any one of the following:
- HF Hospitalization
- Treatment in the Emergency Department (or equivalent) for Heart Failure
- Outpatient treatment for heart failure with intravenous diuretics
AND
- NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomization
- Willing to provide informed consent
Exclusion Criteria:
- Acute coronary syndrome (clinical diagnosis) or cardiac revascularization procedure within 30 days
- Cardiac resynchronization therapy (CRT) within prior 3 months or current plan to implant CRT device
- Active myocarditis, Hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy
- Severe stenotic valvular disease
- Anticipated heart transplantation or ventricular assist device within 12 months
- Chronic inotropic therapy
- Complex congenital heart disease
- End stage renal disease with renal replacement therapy
- Non cardiac terminal illness with expected survival less than 12 months
- Women who are pregnant or planning to become pregnant
- Inability to comply with planned study procedures
- Enrollment or planned enrollment in another clinical trial
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Usual Care
Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines.
This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
|
Zwykła opieka
|
|
Eksperymentalny: Biomarker-Guided Care
Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments.
In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
|
Device: NT-proBNP
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
CV Death or Heart Failure Hospitalization
Ramy czasowe: 24 Months
|
Composite of First Heart Failure Hospitalization or Cardiovascular Mortality
|
24 Months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
All-cause Mortality
Ramy czasowe: 24 months
|
All-cause mortality by treatment arm
|
24 months
|
|
Cumulative Morbidity
Ramy czasowe: 24 months
|
Days alive and not hospitalized for CV reasons
|
24 months
|
|
CV Death
Ramy czasowe: 24 months
|
CV death by treatment arm
|
24 months
|
|
Number of Hospitalizations for First Heart Failure
Ramy czasowe: 24 months
|
First Heart Failure Hospitalization
|
24 months
|
|
Number of Hospitalizations for Recurrent Heart Failure
Ramy czasowe: 24 months
|
Recurrent Heart Failure Hospitalization
|
24 months
|
|
Percentage of Patients With Moderate to Severe Depression
Ramy czasowe: Baseline, 3,6, 12 and 24 months
|
Percentage of patients with moderate to severe depression as measured by the Center for Epidemiologic Studies Depression Scale (CES-D). CES-D is a 20-item scale measuring general depression. Scores range from 0-60, with higher scores indicating greater general depression. Moderate to severe depression is indicated by a score of 11 or higher. |
Baseline, 3,6, 12 and 24 months
|
|
Duke Activity Status Index (DASI)
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
The DASI is a self-administered questionnaire that measures a patient's functional capacity.
It can be used to get a rough estimate of a patient's peak oxygen uptake.
The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity).
|
Baseline, 3, 6, 12 and 24 months
|
|
EQ-5D Health Index
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
The EQ-5D measures the subjects health status in 5 categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and totals them into 1 score, from -0.59 (worst) to 1 (best).
|
Baseline, 3, 6, 12 and 24 months
|
|
EQ-5D Visual Analog Scale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
The EQ-5D VAS records participants self-rated health status on a vertical (0-100) scale with higher scores indicating higher Health-Related Quality of Life, where 0 = worst imaginable health state and 100 = best imaginable health state.
|
Baseline, 3, 6, 12 and 24 months
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score
Ramy czasowe: Baseline, 3, 6,12 and 24 months
|
This KCCQ overall score represents the mean of the following 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation.
Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
|
Baseline, 3, 6,12 and 24 months
|
|
Short Form-36 (SF-36) General Health Subscale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
SF-36 measures perceived Quality of Life.
The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.
|
Baseline, 3, 6, 12 and 24 months
|
|
Short Form-36 (SF-36) Mental Health Subscale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
SF-36 measures perceived Quality of Life.
The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.
|
Baseline, 3, 6, 12 and 24 months
|
|
Short Form-36 (SF-36) Social Functioning Subscale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
SF-36 measures perceived Quality of Life.
The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.
|
Baseline, 3, 6, 12 and 24 months
|
|
Short Form-36 (SF-36) Physiological Functioning Subscale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
SF-36 measures perceived Quality of Life.
The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.
|
Baseline, 3, 6, 12 and 24 months
|
|
Short Form-36 (SF-36) Vitality Subscale
Ramy czasowe: Baseline, 3, 6, 12 and 24 months
|
SF-36 measures perceived Quality of Life.
The following subscales were used: General Health, Mental Health, Social Functioning, Physiological Functioning, and Vitality Each subscale is scored from 0-100 with 0 indicating lowest quality of life.
|
Baseline, 3, 6, 12 and 24 months
|
|
Resource Utilization
Ramy czasowe: 24 months
|
Observed Resource Use
|
24 months
|
|
Resource Utilization Cost
Ramy czasowe: 24 months
|
Observed Hospital-Based Cost.
|
24 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Michael Felker, MD, Duke University
Publikacje i pomocne linki
Publikacje ogólne
- Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Pina IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Fail. 2022 Feb;9(1):77-86. doi: 10.1002/ehf2.13692. Epub 2021 Nov 16.
- Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. J Card Fail. 2021 Dec;27(12):1359-1366. doi: 10.1016/j.cardfail.2021.06.008. Epub 2021 Jun 22.
- Fuery MA, Chouairi F, Januzzi JL, Moe GW, Caraballo C, McCullough M, Miller PE, Reinhardt SW, Clark K, Oseran A, Milner A, Pacor J, Kahn PA, Singh A, Ravindra N, Guha A, Vadlamani L, Kulkarni NS, Fiuzat M, Felker GM, O'Connor CM, Ahmad T, Ezekowitz J, Desai NR. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC Heart Fail. 2021 Jul;9(7):497-505. doi: 10.1016/j.jchf.2021.02.011. Epub 2021 May 12.
- Daubert MA, Yow E, Barnhart HX, Pina IL, Ahmad T, Leifer E, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O'Connor CM, Felker GM. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021 May 18;10(10):e019712. doi: 10.1161/JAHA.120.019712. Epub 2021 May 6.
- Parcha V, Patel N, Kalra R, Suri SS, Arora G, Wang TJ, Arora P. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial. J Am Heart Assoc. 2021 Apr 6;10(7):e018689. doi: 10.1161/JAHA.120.018689. Epub 2021 Mar 23.
- Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pina IL, Patel CB, Anstrom KJ, Cooper LS, Mark D, Leifer ES, Felker GM, Januzzi JL, O'Connor CM. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020 Jul 1;5(7):757-764. doi: 10.1001/jamacardio.2020.0640.
- Januzzi JL Jr, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Mark DB, Pina IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne-Nickens P, Felker GM, O'Connor CM. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 Sep 3;74(9):1205-1217. doi: 10.1016/j.jacc.2019.06.055.
- O'Connor C, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, Adams KF, Pina IL, Anstrom KJ, Cooper LS, Mark DB, Whellan DJ, Januzzi JL Jr, Leifer ES, Felker GM. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. Eur J Heart Fail. 2019 Jun;21(6):770-778. doi: 10.1002/ejhf.1450. Epub 2019 Mar 27.
- Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O'Connor CM, Januzzi J, Felker GM. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC Heart Fail. 2019 Feb;7(2):158-168. doi: 10.1016/j.jchf.2018.10.014. Epub 2019 Jan 2.
- Mark DB, Cowper PA, Anstrom KJ, Sheng S, Daniels MR, Knight JD, Baloch KN, Davidson-Ray L, Fiuzat M, Januzzi JL Jr, Whellan DJ, Pina IL, Ezekowitz JA, Adams KF, Cooper LS, O'Connor CM, Felker GM. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. J Am Coll Cardiol. 2018 Nov 27;72(21):2551-2562. doi: 10.1016/j.jacc.2018.08.2184.
- Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL Jr, Mark DB, Pina IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O'Connor CM. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017 Aug 22;318(8):713-720. doi: 10.1001/jama.2017.10565.
- Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Leifer ES, Mark DB, Desvigne-Nickens P, Paynter G, Pina IL, Whellan DJ, O'Connor CM. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail. 2014 Oct;2(5):457-65. doi: 10.1016/j.jchf.2014.05.007. Epub 2014 Sep 3.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- Pro00033097
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Niewydolność serca
-
Region SkaneRejestracja na zaproszenieNiewydolność serca Klasa II według New York Heart Association (NYHA). | Niewydolność serca Klasa III według New York Heart Association (NYHA).Szwecja
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... i inni współpracownicyZakończonyNiewydolność serca, skurcz | Niewydolność serca ze zmniejszoną frakcją wyrzutową | Niewydolność serca Klasa IV według New York Heart Association | Niewydolność serca Klasa III według New York Heart AssociationPolska
-
University of WashingtonAmerican Heart AssociationZakończonyNiewydolność serca, zastoinowa | Zmiana mitochondrialna | Niewydolność serca Klasa IV według New York Heart AssociationStany Zjednoczone
-
Portuguese Association of Interventional CardiologyMedtronicRekrutacyjnyCiężkie objawowe zwężenie zastawki aortalnej (zdefiniowane jako klasa New York Heart Association (NYHA) ≥ II)Portugalia
Badania kliniczne na Zwykła opieka
-
The University of Texas Health Science Center,...Tufts University; American Heart Association; Michael and Susan Dell FoundationRekrutacyjnyŻywienie w ciąży wysokiego ryzykaStany Zjednoczone
-
Evidence-Based Practice Institute, Seattle, WAZakończonyDepresja | Bezsenność | SamobójstwoStany Zjednoczone
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; Hannover Medical School; University Hospital... i inni współpracownicyAktywny, nie rekrutujący
-
Universitätsklinikum Hamburg-EppendorfWuerzburg University Hospital; University of Kassel; University DüsseldorfRekrutacyjnyZaawansowany nowotwór, różne, BNONiemcy
-
Johnson & Johnson Vision Care, Inc.ZakończonyOstrość wzroku, biomikroskopia w lampie szczelinowej (ocena barwienia rogówki)Stany Zjednoczone
-
University of AlbertaUniversity Hospital FoundationZakończonyMigotanie przedsionkówKanada
-
Yonsei UniversityJeszcze nie rekrutacjaMigotanie przedsionkówKorea Południowa
-
Chung Shan Medical UniversityZakończony
-
University of Kansas Medical CenterBioNexus KC; Blue KC (Blue Cross Blue Shield)ZakończonyZwiązane z ciążą | Opieka prenatalna | Dula Care | Zdrowie czarnej matki i niemowlątStany Zjednoczone
-
Weill Medical College of Cornell UniversityCornell UniversityWycofaneObciążenie opiekunaStany Zjednoczone